---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-003470"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:41:23.365322+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharmaceuticals reports Q3 2021 cash of $296.5M, ORIC-101 early clinical data, and upcoming pipeline milestones

## Summary
- Cash, cash equivalents and investments of $296.5 million, expected to fund operations into 2024.
- Initial Phase 1b data for ORIC-101 combo with enzalutamide showed safe profile and antitumor activity in 6 of 8 key patients.
- R&D expenses $12.9M (Q3 2021) vs $8.8M (Q3 2020); G&A expenses $5.6M vs $3.8M.
- Anticipated Q4 2021 milestones: initiate Phase 1 trial for ORIC-533 in multiple myeloma and file IND for ORIC-944.

## SEC filing metadata
- accession: 0000950170-21-003470
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017021003470/0000950170-21-003470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017021003470/oric-20211108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-003470
- JSON: https://secwatch.observer/filing/0000950170-21-003470.json
- Plain text: https://secwatch.observer/filing/0000950170-21-003470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.